Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy

Purpose: Over the past 60 years, cytotoxic chemotherapy has targeted the cancer cell. Despite this, there have been few cancer cures. A new approach to cancer therapy is to target the multicellular biological entity of the tumor microenvironment. Experimental Design: Lenalidomide, an immunomodulatory drug, sunitinib, a tyrosine kinase inhibitor, and low-dose metronomic cyclophosphamide, were tested alone and in combination for their abilities to inhibit endothelial cell tube formation, rat aortic ring outgrowth, tumor growth, and metastatic development in mice. In addition, ectopic tumor lysates were evaluated for the presence of proangiogenic proteins. Results: The three agents alone were shown to significantly inhibit endothelial cells' ability to form tubes and significantly inhibit the multicellular microenvironment in the rat aortic ring assay (P < 0.01 and P < 0.001). This effect was also significantly augmented when the agents were combined. Furthermore, the three-drug combination was able halt the progression of tumor growth almost completely in xenograft models of ocular melanoma, colon cancer, pancreatic cancer, and cutaneous melanoma. These agents significantly decrease the number of proliferating cells in tumors, significantly increase the number of cells undergoing active cell death in tumors, and significantly decrease the number of blood vessels in treated tumors (P < 0.05). Combination therapy shows a decrease in the compensatory up-regulation of proangiogenic proteins after treatment when compared with single-agent therapy. Conclusions: This combination of agents causes an inhospitable microenvironment for tumor cells and shows great promise for use in the clinic.

[1]  G. Mundy.  The premetastatic niche , 2008 .

[2]  S. Libutti,et al.  Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma , 2007, Journal of Translational Medicine.

[3]  Michael I Dorrell,et al.  Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis , 2007, Proceedings of the National Academy of Sciences.

[4]  S. Rafii,et al.  Preparing the "soil": the premetastatic niche. , 2006, Cancer research.

[5]  P. Schafer,et al.  Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. , 2006, Leukemia research.

[6]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[8]  C. Betsholtz.  Insight into the physiological functions of PDGF through genetic studies in mice. , 2004, Cytokine & growth factor reviews.

[9]  A. Dalgleish,et al.  The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.

[10]  R. Kerbel,et al.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.

[11]  D. Stupack,et al.  Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli , 2003, Science.

[12]  Tobias Sjöblom,et al.  PDGF receptors as cancer drug targets. , 2003, Cancer cell.

[13]  P. Haslett,et al.  Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. , 2003, The Journal of infectious diseases.

[14]  A. Dalgleish,et al.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects , 2002, British Journal of Cancer.

[15]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[16]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[17]  N. Munshi,et al.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.

[18]  P. Duray,et al.  Approaches to preclinical screening of antiangiogenic agents. , 2001, Seminars in oncology.

[19]  G Muller,et al.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.

[20]  Gabriele Bergers,et al.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.

[21]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[22]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[23]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[24]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[25]  U. Rapp,et al.  Endothelial apoptosis in Braf-deficient mice , 1997, Nature Genetics.

[26]  R. Kerbel,et al.  Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[27]  S. Paget.  The distribution of secondary growths in cancer of the breast. 1889. , 1989, Cancer metastasis reviews.

[28]  R. Novak,et al.  Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene. , 1986, Biochemical and biophysical research communications.

[29]  L. Liotta,et al.  Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. , 1982, Biochemistry.

[30]  H. Skipper,et al.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.

[31]  H. Skipper,et al.  Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. , 1963, Cancer research.

[32]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[33]  Dong-Kug Choi,et al.  Thalidomide and Lenalidomide Extend Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis , 2006, The Journal of Neuroscience.

[34]  A. Dalgleish,et al.  Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. , 2005, Microvascular research.

[35]  A. Ostman.  PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. , 2004, Cytokine & growth factor reviews.

[36]  R. S. Go,et al.  The rat aortic ring assay for in vitro study of angiogenesis. , 2003, Methods in molecular medicine.

[37]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  J C Bailar,et al.  Cancer undefeated. , 1997, The New England journal of medicine.